Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Privia Health (PRVA) delivered earnings and revenue surprises of -12.50% and +8.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Investment management company Vulcan Value Partners recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Vulcan Value Partners prioritizes long-term returns and lower risk over short-term performance. In the quarter, the Large Cap Composite (Net) returned 9.5%, the Small Cap Composite (Net) returned 13.3%, the Focus Composite (Net) returned 10.4%, the […]
Veeva Systems (VEEV) is drawing fresh attention after being removed from several Russell growth indices. This shift coincides with solid recent earnings trends and a mixed share price performance this year. See our latest analysis for Veeva Systems. The recent index removals come after a strong rebound in the stock, with a 30 day share price return of 13.13% and a 90 day gain of 25.27%. However, this contrasts with a year to date share price decline of 13.57% and a 1 year total shareholder...
Though Veeva Systems has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
A number of stocks fell in the afternoon session after the Federal Reserve held its benchmark rate at 3.5%–3.75%, unchanged since the central bank cut by three-quarters of a point in late 2025, and then delivered a dot plot that told investors the easing cycle underpinning the sector's re-rating might be over.
Despite GE HealthCare's underperformance relative to the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead
Veeva Systems (VEEV) closed the most recent trading day at $156.33, moving 1.94% from the previous trading session.
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -519.58% and -1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
